Eli Lilly is capping the price of insulin at $35 a month. The other two companies that are competitive in this market, novo, Nordisk and Sanofi, are under pressure to match what Eli Lilly has done. "I wouldn't be surprised if in relatively short order, we see these other companies do the same thing," he says.
Insulin was the poster child of overpriced life saving drugs, but a manufacturer finally capped the cost at $35. Vox’s Dylan Scott explains how pharmaceutical companies for decades managed to overprice drugs Americans desperately needed.
This episode was produced by Haleema Shah, edited by Amina Al-Sadi, fact-checked by Laura Bullard and Matt Collette, engineered by Patrick Boyd, and hosted by Sean Rameswaram.
Transcript at vox.com/todayexplained
Support Today, Explained by making a financial contribution to Vox! bit.ly/givepodcasts
Learn more about your ad choices. Visit podcastchoices.com/adchoices